LaunchTrends: Otezla (US) (Wave 3) | 2015

Psoriatic arthritis (PsA) is an inflammatory joint disease that is highly comorbid with psoriasis, and characterized by pain, stiffness, and/or swelling in the joints, ligaments, and tendons. In March of 2014, apremilast (Otezla) became the first oral therapy approved and launched for the treatment of active PsA in the United States. This report tracks the postlaunch awareness, trial, and usage of Otezla among surveyed rheumatologists for the treatment of PsA. The third wave of the syndicated report assesses physician perceptions at one year after the launch of Apremilast.

launch Related Market Assessment Reports